Purple Biotech Ltd. PPBT
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Purple Biotech Ltd. (PPBT) is a healthcare company listed in the US with a market value of about $3M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -37%.
About Purple Biotech
Purple Biotech is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. It was profitable in 6 of the last 10 years in our data.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$26M | -$7M | -$20M | -$22M | $18M | $29M | $5M | $5M | $12M | $12M |
| Free cash flow | -$6M | — | -$20M | -$17M | -$489000 | $2M | -$2M | -$8M | -$9M | -$6M |
| EPS (diluted) | $-16.22 | $-4.45 | $-12.22 | $-13.32 | $10.96 | $17.64 | $3.32 | $3.20 | $7.48 | $7.45 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | — | — | -51.4% | -38.1% | -21.9% | -12.6% | -54.2% | -58.8% | -127.6% | -42.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Purple Biotech pay a dividend?
Not currently.
Is Purple Biotech a good stock to buy?
We do not give buy or sell advice. Purple Biotech scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.